ABSTRACT

IL-32 acts as a pro-inflammatory cytokine by inducing the synthesis of inflammatory molecules as well as promoting the morphological changes involved in the transformation of monocytes into osteoclasts (OCs). Evaluation of the functions of IL-32 has mainly focused on its inflammatory properties, such as involvement in the pathogenesis of various autoimmune diseases. Recently, IL-32 was shown to be involved in bone metabolism, in which it promotes the differentiation and activation of OCs and plays a key role in bone resorption in inflammatory conditions. IL-32γ also regulates bone formation in conditions such as ankylosing spondylitis and osteoporosis. In this review, we summarize the results of recent studies on the role of IL-32γ in bone metabolism in inflammatory arthritis.

Keywords: IL-32; Rheumatoid arthritis; Ankylosing spondylitis; Inflammation; Osteoclasts; Osteoblasts

INTRODUCTION

Chronic inflammatory conditions such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) disrupt the balance of bone homeostasis by accelerating the formation of osteoclasts (OCs) or osteoblasts (OBs) (1,2). Bone destruction in RA is caused by a combination of inflammatory cytokines, such as tumor necrosis factor (TNF)-α, IL-6, and IL-17, in the affected joints, which induce differentiation and activation of OCs (1). Although TNF-α and IL-17 are pivotal cytokines that regulate inflammation in AS, the main feature of joints in AS are bony ankyloses characterized by excessive OB activation leading to the formation of syndesmophytes (2). Considering the differences between RA and AS, a novel cytokine associated with pathological bone metabolism may exist.

IL-32, also known as natural killer cell protein 4 (NK4), has been defined as an inflammatory cytokine involved in infection, cancer, chronic inflammation, and autoimmune diseases (3-7). In response to various inflammatory stimuli, IL-32 is produced by both immune and non-immune cells, including NK cells, T cells, monocytes, epithelial cells, endothelial cells, and fibroblasts (8-10). During infection, IL-32 activates inducible nitric oxide synthase, interferon (IFN)-γ, and IL-6, resulting in antiviral effects (11). Further, IL-32γ transgenic (TG) mice have shown resistance to lipopolysaccharide-mediated septic shock by reducing...
systemic cytokine release, indicating a protective effect against bacterial infection (12). IL-32 expression is high in a variety of cancers, including gastric cancer, lung cancer, hepatocellular carcinoma, and pancreatic cancer (13-16). IL-32 promotes the growth, invasion, and metastasis of tumors (13,14).

In humans, there are at least 9 different isoforms of IL-32 (IL-32α, IL-32β, IL-32γ, IL-32δ, IL-32ε, IL-32ζ, IL-32θ, and IL-32η) generated by alternative splicing (17). IL-32γ is the longest (full protein) and most active isoform in terms of stimulating peripheral blood mononuclear cells (PBMCs) or producing pro-inflammatory cytokines in macrophages (18). IL-32α, which is the most abundant isoform, is the shortest and the least active pro-inflammatory isoform (18). The detailed functions of these individual isoforms and their corresponding receptors, as well as why there are up to 9 different isoforms, remain unclear (19). However, a previous study suggested that splicing of IL-32γ to shorter isoforms represents a safety switch mechanism to protect against uncontrolled and exaggerated inflammation (20).

Among the isoforms of IL-32, IL-32γ has been shown to be involved in the pathogenesis of RA and AS, both of which are inflammatory joint diseases (21-23). In this review, we describe the multifaceted role of IL-32γ, particularly in bone-related phenotypes in chronic inflammatory autoimmune arthritis, and explain the distinct clinical aspects of RA and AS involving this cytokine.

## ROLE OF IL-32 IN INFLAMMATORY DISEASES

IL-32 has diverse roles in mediating chronic inflammation and autoimmunity (6). An elevated concentration of serum IL-32 has been observed in patients with granulomatosis with polyangitis (GPA) (24) and those with chronic obstructive pulmonary disease (COPD) (25). In GPA, the IL-32 concentration was elevated and altered according to the treatment response. Neutrophil proteinase 3 (PR3) is a major autoantigen of GPA (24), and IL-32α binds to PR3 with high affinity (26). By inducing proinflammatory cytokines such as TNF-α and IL-6 and binding to PR3, IL-32 appears to be closely associated with responsiveness to treatment in patients with GPA (24). In COPD, increased serum concentrations of IL-32 correlates with smoking status (25). Inflammation in COPD is induced by type 1 helper T cells and the production of cytokines, such as IFN-γ (27,28). IFN-γ is one stimulator of IL-32 production (8). Thus, an increased serum concentration of IL-32 in patients with COPD can be explained by the increased levels of IFN-γ (25). Moreover, expression of IL-32 in the lung tissue of patients with COPD has been shown to be negatively correlated with lung function parameters and positively correlated with TNF-α expression, number of CD8+ cells infiltrating lung tissue, and phosphorylation state of p38 mitogen-activated protein (9). Thus, IL-32 has been implicated in COPD immune response and disease progression (9).

IL-32 is also associated with the progression and pathophysiology of inflammatory bowel diseases (6,29). The secretion of IL-32 is enhanced by the intracellular nucleotide oligomerization domains and muramyl dipeptide, which is a peptidoglycan fragment from bacteria and potent nucleotide oligomerization domain 2 ligand that induces the expression of IL-32 in a caspase-1-dependent manner (30). This leads to increased production of IL-6 and IL-1β (30,31). IL-32ε, an isoform of IL-32, has been identified in human colonic subepithelial myofibroblasts and found to be enhanced in the inflamed mucosa of patients

---

Author Contributions

Writing - original draft: Kwon OC, Chang EJ, Kim YG; Writing - review & editing: Kim S, Hong S, Lee CK, Yoo B, Chang EJ, Kim YG.

https://doi.org/10.4110/in.2018.18.e20

https://immunenetwork.org
with inflammatory bowel disease (32). The role of IL-32 in bowel inflammation has been investigated in vivo using IL-32γ TG mice (3,33), in which an increased concentration of IL-32γ was associated with faster and more severe progression of acute bowel inflammation compared to wild-type (WT) mice. However, the degree of colonic inflammation was lower, and the survival rate was higher, with dextran sodium sulfate-induced colitis in IL-32γ TG mice (3,33). The lower degree of inflammation can be explained by the splicing of IL-32γ into IL-32β, which may induce IL-10 and lead to an increased anti-inflammatory response (34).

In systemic lupus erythematosus (SLE), the importance of IL-32 remains controversial. One study found no significant difference in the serum concentrations of IL-32 between SLE patients and healthy controls (35), whereas another study reported a high concentration of IL-32γ in some patients with SLE with lupus nephritis (36). Despite anecdotal reports showing increased serum concentrations of IL-32γ in SLE, the functional role of IL-32γ in SLE pathogenesis is unclear. Additionally, it remains unknown whether the serum concentrations of other IL-32 isoforms are elevated in SLE. Further studies are required to confirm the roles of IL-32γ and other isoforms in patients with SLE.

In a study of skin disorders, an association between IL-32 and atopic dermatitis has been reported. One study showed that human keratinocytes express high levels of IL-32 under stimulation by IFN-γ, TNF-α, and type 1 helper T cells (37). Further, transfection of keratinocytes with small interfering RNA to IL-32 significantly reduced keratinocyte apoptosis, suggesting that IL-32 stimulates apoptosis of keratinocytes. Expression of IL-32 was increased in skin biopsy specimens from patients with atopic dermatitis compared to those from healthy donors or patients with psoriasis, showing that IL-32 contributes to the development of atopic dermatitis by stimulating the apoptosis of keratinocytes.

The association of IL-32 with disease activity is also evident in RA, as shown by the positive correlation of IL-32γ with TNF-α in the peripheral blood of active patients with RA (38). TNF-α and IL-1β stimulate the production of IL-32γ from RA fibroblast-like synoviocytes (FLS) (38), and the concentration of IL-32γ has been shown to be elevated in the joint fluid of patients with RA (23). Additionally, joint swelling, inflammatory cell infiltration, and cartilage damage can be induced by injecting IL-32γ into mice knee joints (39), and severe synovitis and cartilage damage can be induced in IL-32α TG mice (and not WT mice) with lipopolysaccharide knee injections (40).

A recent report showed that a high concentration of IL-32γ accumulated in the joint of patients with AS and IL-32γ was expressed in the synovia of AS patients at a much higher concentration than in the synovia of RA patients (22). However, the concentration of IL-32γ in the peripheral joints was not significantly correlated with systemic inflammation and AS activity indices (22).

**ROLE OF IL-32 IN BONE METABOLISM**

**OC and bone resorption by IL-32γ**

In RA, which is characterized by chronic synovitis and hyperplasia, the joints are the representative pathological sites of progressive cartilage and bone destruction (41). Activated macrophages are the predominant cell type in the inflamed synovial tissue and are responsible for promoting inflammation via the production of inflammatory cytokines,
such as TNF-α, IL-17, IL-1β, and IL-6 (41). These cytokines promote the differentiation of preosteoclasts into mature OCs, enhance bone resorption, and prolong OC survival, thereby contributing to bony erosion in inflamed joints (42). Receptor activator of NF-κB ligand (RANKL), which binds to RANK, is a key molecule in the differentiation of OCs (43). RANKL is a membrane-bound homotrimeric protein found in the OB lineage, and its soluble form (sRANKL) is abundantly produced from FLS in conditions associated with joint inflammation, such as RA (44). TNF-α induces RANKL and RANK expression and thereby stimulates OC differentiation via RANKL-induced osteoclastogenesis (45,46). Additionally, TNF-α can directly induce OC differentiation in the absence of RANKL by activating NF-κB signaling (47). IL-17 stimulates RANKL expression and thus RANKL-induced osteoclastogenesis (48). However, in the absence of RANKL, IL-17 can also induce OC differentiation by enhancing TNF-α-induced osteoclastogenesis (49).

Expression of IL-32 in synovial tissue has been extensively studied in patients with RA (23,39,50). Joosten et al. (39) reported that IL-32 was elevated in RA synovial tissue compared to tissues from patients with osteoarthritis and healthy controls, and that the expression of IL-32 in synovial staining correlated with synovial inflammation and the serum erythrocyte sedimentation rate. Furthermore, in a comparison of joint inflammation in WT mice versus TNF-α gene knockout mice after IL-32γ injection into the joint, TNF-α gene knockout mice showed no evidence of joint swelling and had reduced numbers of inflammatory cells in their synovial tissue compared to WT mice (39). This shows that IL-32γ-mediated joint inflammation in RA synovial tissues is at least in part TNF-α-dependent (39). The relationship between IL-32β and TNF-α in vivo was studied by Shoda et al. (10) using a collagen-induced arthritis model. Transfer of IL-32β-producing CD4+ T cells to collagen-immunized mice exacerbated collagen-induced arthritis, with TNF-α blockade attenuating this exacerbation, revealing a close association between IL-32β and TNF-α (10). Furthermore, RA-derived FLSs produce IL-32 in response to TNF-α in a dose-dependent manner, suggesting that the inflammatory cascade in the synovial tissue of RA can be amplified by IL-32 activity via an autocrine loop (50).

The first study of IL-32 and OCs was carried out using IL-32α by Mabilleau and Sabokbar (51); they investigated the effect of IL-32α on OC differentiation and activation. OC differentiation is a process in which OC precursors develop into mature OCs, which express genes that typify the OC lineage (NFATc1 [NFATc1], TNF receptor-associated factor 6, OC-associated receptor and cathepsin K) (52). In contrast, OC activation is a process in which mature OCs are activated, resulting in the initiation of bone resorption (52). Mabilleau and Sabokbar (51) reported that IL-32α induced the differentiation of OCs but did not activate these multinucleated cells into bone-resorbing OCs. However, IL-32γ, the isoform with a more potent biological mechanism for stimulating PBMCs than IL-32α (18), stimulates and activates OC differentiation, which can be confirmed in a bone resorption assay. This protein is activated via NFATc1 activity and exerts synergistic effects with RANKL on osteoclastogenesis (23). According to a previous study (18), the biological activities in TNF-α and IL-6 secretion from PBMCs differed between the IL-32α and IL-32γ, suggesting that the different biological activities of the 2 isoforms were attributed to differences in OC activity.

Interestingly, the synergistic effect of RANKL-induced signaling and IL-32γ on osteoclastogenesis was demonstrated by treating cells with IL-32γ at the fusion stage (53). Kim et al. (23) demonstrated that IL-32γ induced the expression of dendritic cell-specific transmembrane protein, which suggests that IL-32γ is a mediator of OC fusion. Furthermore,
IL-32γ can induce the differentiation of CD14+ monocytes into OCs even in the absence of sRANKL stimulation; however, bone-resorbing activity is not sufficient in RANKL-independent IL-32γ-induced OCs.

In contrast, IL-32γ suppresses the transcription of osteoprotegerin in RA-FLS and OBs (21,23). Collectively, IL-32γ forms an osteoclastogenic environment in patients with RA by promoting OC differentiation, exhibiting synergistic effects with RANKL, and suppressing osteoprotegerin (23). Thus, inhibition of IL-32γ under RANKL-rich conditions including RA may be useful for delaying or preventing inflammation or tissue destruction.

**OB and bone formation by IL-32γ**

AS is a chronic inflammatory form of arthritis that primarily affects the spine and large joints. New bone formation in AS may be related to an active repair process following damage caused by inflammation (54,55), which is bone remodeling characterized by sequential and local communication between OBs and OCs (56). Previous reports showed that IL-32γ stimulates OC formation in vitro (7,23,57,58) while actively enhancing OB differentiation (21,22), indicating a physiological role for IL-32γ in the bone remodeling process.

Lee et al. (22) first reported the pathogenic role of IL-32γ in AS and OB differentiation using IL-32γTG mice. Although the TNF-α concentration was not significantly different between AS and RA joint fluids, IL-32γ accumulated in the inflamed joints of patients with AS at a much higher degree than in patients with RA. Additionally, immunohistochemical staining revealed high expression of IL-32γ in the paravertebral soft tissues and peripheral synovia in patients with AS. Moreover, IL-32γTG mice showed a higher degree of osteogenic differentiation compared to WT mice and administration of IL-32γ induced OB differentiation actively in vitro (21,22). These data suggest that IL-32γ is involved in AS pathogenesis, particularly in bone progression.

Dickkopf-1 (DKK-1) is a potent Wnt pathway inhibitor produced by OBs and is known to suppress OB differentiation. Serum DKK-1 concentrations are inversely correlated with spinal bone progression in patients with AS (59), and blockade of DKK-1 promotes the formation of ankylosis of sacroiliac joints in model mice (60). Recently, Lee et al. (21) demonstrated a relationship between IL-32γ and DKK-1 in bone metabolism and the functional mechanism of osteogenesis mediated by systemic IL-32γ. In their study, human IL-32γTG mice showed increased bone formation and reduced trabecular bone loss induced by ovariectomy (21). To clarify the molecular mechanism of IL-32γ-mediated downregulation of DKK-1, the authors also investigated the differential regulation of microRNAs by IL-32γ. Interestingly, miR-29a in primary OBs from IL-32γTG mice was expressed at a significantly higher level than in the WT group (21). However, despite the protective function of IL-32γ in bone loss demonstrated in the study, the regulatory mechanism of IL-32γ alteration — except for the role of miR-29a — was not conclusively determined.

Furthermore, a study found that among osteoporosis patients, hip fracture victims had lower IL-32γ concentrations in their blood than those who did not experience hip fractures (21). The same study found that patients with factured hips had higher DKK-1 blood concentrations than those with intact hips. Interestingly, there was no significant difference in the bone marrow concentrations of IL-32γ between osteoporosis patients with and without hip fractures, indicating that reduction of systemic IL-32γ rather than local IL-32γ is responsible for osteoporotic fractures (21). Thus, in patients with osteoporosis,
a combination of low IL-32γ and high DKK-1 concentration in the blood can be used as a predictive marker for osteoporotic fracture.

Collectively, IL-32γ may act as a key regulator in the pathogenesis of AS by controlling DKK-1 expression, leading to modulation of Wnt/β-catenin signaling. Therefore, IL-32γ may be a promising novel molecular target for preventing atypical bone formation in patients with AS (22).

CONCLUSION

IL-32γ is involved in bone changes associated with inflammatory arthritides, such as RA and AS. IL-32γ, through its synergistic effects with RANKL secreted from RA-FLSs and OBs, promotes OC formation and activation and contributes to inflammatory bone loss in RA. In contrast, locally elevated IL-32γ in AS may be associated with excessive bone formation by enhancing OB differentiation via inhibition of DKK-1.

ACKNOWLEDGEMENTS

This work was supported by grants from the National Research Foundation of Korea to YG Kim (2014R1A1A2053476) and EJ Chang (2014R1A1A2056099). We thank Dr. Joon Seo Lim from the Scientific Publications Team at Asan Medical Center for his editorial assistance in preparing this manuscript.
REFERENCES

1. Jung SM, Kim KW, Yang CW, Park SH, Ju JH. Cytokine-mediated bone destruction in rheumatoid arthritis. *J Immunol Res* 2014;2014:263625.

2. Lories R. The balance of tissue repair and remodeling in chronic arthritis. *Nat Rev Rheumatol* 2011;7:700-707.

3. Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammations. *Eur J Med Res* 2015;20:7.

4. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. *Ann Rheum Dis* 2006;65 Suppl 3:iii61-iii64.

5. Khawar MB, Abbasi MH, Sheikh N. Il-32: a novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. *Meditators Inflamm* 2016;2016:8413768.

6. Kim S. Interleukin-32 in inflammatory autoimmune diseases. *Immune Netw* 2014;14:123-127.

7. Xu WD, Zhang M, Feng CC, Yang XK, Pan HF, Ye DQ. IL-32 with potential insights into rheumatoid arthritis. *Clin Immunol* 2013;147:89-94.

8. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFα. *Immunity* 2005;22:131-142.

9. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2008;178:894-901.

10. Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. *Arthritis Res Ther* 2006;8:R166.

11. Zhou Y, Zhu Y. Important role of the IL-32 inflammatory network in the host response against viral infection. *Viruses* 2015;7:3116-3129.

12. Kim SJ, Lee S, Kwak A, Kim E, Jo S, Bae S, Lee Y, Ryoo S, Choi J, Kim S. Interleukin-32γ transgenic mice resist LPS-mediated septic shock. *J Microbiol Biotechnol* 2014;24:1133-1142.

13. Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, Kim EH, Park DK, Kim SH, et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. *J Microbiol Biotechnol* 2008;18:1606-1612.

14. Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. *Am J Respir Crit Care Med* 2009;180:769-779.

15. Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. *J Biol Chem* 2009;284:17868-17876.

16. Kang VH, Park MY, Yoon DY, Han SR, Lee CI, Ji NY, Myung PK, Lee HG, Kim JW, Yeon YM, et al. Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. *Cancer Lett* 2012;318:226-233.

17. Kang JW, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, Park SH, Kim H, Ahn JH, Hong JT, et al. Interaction network mapping among IL-32 isoforms. *Biochimie* 2014;101:248-251.

18. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, Choi WS, Kim BK, Lee CK, Yoon DY, et al. Identification of the most active interleukin-32 isoform. *Immunology* 2009;126:535-542.
19. El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, Goulet IP, van Grevenynghe I, Lee T, Singer J, et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Sci Rep 2016;6:22902. PUBMED | CROSSREF

20. Heinhuus B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine 2012;60:321-327. PUBMED | CROSSREF

21. Lee EI, Kim SM, Choi B, Kim EY, Chung YH, Lee EI, Yoo B, Lee CK, Hong S, Kim BI, et al. Interleukin-32 gamma stimulates bone formation by increasing mir-29a in osteoblastic cells and prevents the development of osteoporosis. Sci Rep 2017;7:40240. PUBMED | CROSSREF

22. Lee EI, Lee EJ, Chung YH, Song DH, Hong S, Lee CK, Yoo B, Kim TH, Park YS, Kim SH, et al. High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation. Arthritis Res Ther 2015;17:350. PUBMED | CROSSREF

23. Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B. Effect of interleukin-32y on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum 2010;62:515-523. PUBMED

24. Bae S, Kim YG, Choi J, Hong J, Lee S, Kang T, Jeon H, Hong K, Kim E, Kwak A, et al. Elevated interleukin-32 expression in granulomatosis with polyangitis. Rheumatology (Oxford) 2012;51:1979-1988. PUBMED | CROSSREF

25. Gasioriene E, Lavinskiene S, Sakalauskas R, Sitkauskiene B. Levels of il-32 in serum, induced sputum supernatant, and bronchial lavage fluid of patients with chronic obstructive pulmonary disease. COPD 2016;13:569-575. PUBMED | CROSSREF

26. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A 2006;103:3316-3321. PUBMED | CROSSREF

27. Koutsokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respir Res 2013;14:111. PUBMED | CROSSREF

28. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8:183-192. PUBMED | CROSSREF

29. Damen MS, Popa CD, Netea MG, Dinarello CA, Joosten LA. Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. Atherosclerosis 2017;264:83-91. PUBMED | CROSSREF

30. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A 2005;102:16309-16314. PUBMED | CROSSREF

31. Peyrin-Biroulet L, Vignal C, Dessein R, Simonet M, Desreumaux P, Chamaillard M. NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. Trends Microbiol 2006;14:432-438. PUBMED | CROSSREF

32. Imaeda H, Andoh A, Aomatsu T, Osaki R, Bamba S, Inatomi O, Shimizu T, Fujiyama Y. A new isoform of interleukin-32 suppresses IL-8 mRNA expression in the intestinal epithelial cell line HT-29. Mol Med Rep 2011;4:483-487. PUBMED

33. Choi J, Bae S, Hong J, Ryoo S, Jhung H, Hong K, Yoon D, Lee S, Her E, Choi W, et al. Paradoxical effects of constitutive human IL-32y in transgenic mice during experimental colitis. Proc Natl Acad Sci U S A 2010;107:21082-21086. PUBMED | CROSSREF

34. Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS, Kim SH, Han JY, Yoon DY. A proinflammatory cytokine interleukin-32β promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 2009;128:e532-e540. PUBMED | CROSSREF

35. Zhang M, Xu WD, Zhu Y, Wen PF, Leng RX, Pan HF, Ye DQ. Serum levels of cytokines in systemic lupus erythematosus: association study in a Chinese population. Z Rheumatol 2014;73:277-280. PUBMED | CROSSREF
36. Inoue M, Shoda H, Seri Y, Kubo K, Kanda H, Fujio K, Yamamoto K. Three cases of lupus nephritis patients with serum interleukin-32γ detection. *Lupus* 2014;23:1187-1191. [PUBMED] [CROSSREF]

37. Meyer N, Zimmermann M, Bürgler S, Bassin C, Woehrl S, Moritz K, Rhyner C, Indermittte P, Schmid-Grendelmeier P, Akdis M, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. *J Allergy Clin Immunol* 2010;125:858-865.e10. [PUBMED] [CROSSREF]

38. Heinhus B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LA. Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritis. *Proc Natl Acad Sci U S A* 2011;108:4962-4967. [PUBMED] [CROSSREF]

39. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgren B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. *Proc Natl Acad Sci U S A* 2006;103:3298-3303. [PUBMED] [CROSSREF]

40. Nakayama M, Niki Y, Kawasaki T, Takeda Y, Horiuchi K, Sasaki A, Okada Y, Umezawa K, Igegami H, Toyama Y, et al. Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha. *Arthritis Res Ther* 2012;14:R120. [PUBMED] [CROSSREF]

41. Lee EJ, Choi B, Hwang ES, Chang EJ. Interleukin-32 gamma as a new face in inflammatory bone diseases. *J Rheum Dis* 2017;24:14-20. [CROSSREF]

42. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat Rev Immunol* 2007;7:429-442. [PUBMED] [CROSSREF]

43. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. *Nat Rev Immunol* 2007;7:292-304. [PUBMED] [CROSSREF]

44. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. *Arthritis Rheum* 2000;43:250-258. [PUBMED] [CROSSREF]

45. Komine M, Mukita A, Mukita T, Ogata Y, Hotobeuchi T, Kohashi O. Tumor necrosis factor-α cooperates with receptor activator of nuclear factor κB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. *Bone* 2001;28:474-483. [PUBMED] [CROSSREF]

46. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. *J Clin Invest* 2005;115:3418-3427. [PUBMED] [CROSSREF]

47. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. *J Biol Chem* 2000;275:4858-4864. [PUBMED] [CROSSREF]

48. Lubberts E, van den Busselaar L, Oppers-Walgren B, Schwarzengerber P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. *J Immunol* 2003;170:2655-2662. [PUBMED] [CROSSREF]

49. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, Kotake S. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: a novel mechanism of osteoclastogenesis by IL-17. *J Cell Biochem* 2009;108:947-955. [PUBMED] [CROSSREF]

50. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, Kim DK, Kim HS, Choi JD, Kim SH, et al. Tumor necrosis factor α-induced interleukin-32 is positively regulated via the Syk/protein kinase Cδ/JNK pathway in rheumatoid synovial fibroblasts. *Arthritis Rheum* 2009;60:678-685. [PUBMED] [CROSSREF]

51. Mabilleau G, Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. *PLoS One* 2009;4:e4173. [PUBMED] [CROSSREF]

52. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;423:337-342. [PUBMED] [CROSSREF]
53. Kim YG, So MW, Koo BS, Chang EJ, Song SI, Lee CK, Yoo B. The influence of interleukin-32γ on osteoclastogenesis with a focus on fusion-related genes. *J Clin Immunol* 2012;32:201-206.

54. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. *Arthritis Rheum* 2008;58:649-656.

55. Schett G, Rudwaleit M. Can we stop progression of ankylosing spondylitis? *Best Pract Res Clin Rheumatol* 2010;24:363-371.

56. Matsuo K, Irie N. Osteoclast-osteoblast communication. *Arch Biochem Biophys* 2008;473:201-209.

57. Moon YM, Yoon BY, Her YM, Oh HJ, Lee IS, Kim KW, Lee SY, Woo YJ, Park KS, Park SH, et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. *Arthritis Res Ther* 2012;14:R246.

58. Kundu M, Basu J. IL-32: an emerging player in the immune response network against tuberculosis? *PLoS Med* 2006;3:e274.

59. Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L. Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. *Clin Lab* 2014;60:1527-1531.

60. Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G. Blockade of dickkopf (DKK)-1 induces fusion of sacroiliac joints. *Ann Rheum Dis* 2010;69:592-597.